NVLX just announced huge breaking news: Nuvilex Announces Name Change to PharmaCyte Biotech (Read Press Release Below) This Could be an Added Catalyst for a Major Breakout! If you haven`t taken a look at NVLX yet, this may be the last chance in this range! Start your research immediately! PRESS RELEASE:
Nuvilex Announces Name Change to PharmaCyte Biotech Company`s Shares Will Trade Under New Ticker Symbol PHCB SILVER SPRING, Md., Jan. 7, 2015 (GLOBE NEWSWIRE) — Nuvilex, Inc.
(NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change is part of the Company`s transformation process to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box(R) technology, a proprietary cell encapsulation platform being utilized to develop “targeted” treatments for solid cancerous tumors and insulin dependent diabetes.
“Over the past year, we`ve implemented an aggressive strategy to facilitate the advancement of the treatments we are developing for cancer and diabetes, with our Cell-in-a-Box(R) technology at the core of these treatments. Our new name reflects the tremendous progress we`ve accomplished in terms of clinical development and signifies the structural completion of our transition to becoming a fully dedicated biotechnology company,” said Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
Some of the highlights in 2014 that have marked this transition include:
Receiving “orphan drug” designation from the U.S. Food and Drug Administration (FDA) for the Company`s pancreatic cancer treatment, with applications filed with the EMA and the TGA for the same status in Europe and Australia.
Development of a clinical protocol for a planned Phase 2b clinical trial with the goal of initiating the clinical trial in 2015.
A preclinical study being completed evaluating the effectiveness of the Company`s pancreatic cancer treatment on the accumulation of malignant ascites fluid often associated with the growth of abdominal cancers with positive results that have led to a follow-up study about to be launched.
The establishment of a world-wide Diabetes Consortium with a number of research agreements now in place with major universities and institutions that will permit the development of a break-through treatment for insulin dependent diabetes that combines Cell-in-a-Box(R) with insulin-producing cells.
Progression at the University of Northern Colorado in the pursuit of treatments for brain and other forms of difficult to treat cancers that will combine cannabinoid or cannabinoid-like compounds with the Cell-in-a-Box(R) technology.
“With exciting developments on the horizon for 2015, our work to develop treatments for both cancer and diabetes will move forward under our new name because it speaks to what we actually do here at PharmaCyte Biotech,” concluded Mr. Waggoner.
About PharmaCyte Biotech PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.
PharmaCyte Biotech`s treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or “cancer-killing” form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of marijuana known as cannabinoids. In doing so, PharmaCyte Biotech is examining ways to exploit the benefits of Cell-in-a-Box(R) technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. This provides PharmaCyte Biotech the rare opportunity to develop “green” approaches to fighting deadly diseases, such as cancer of the pancreas, brain and breast, which affect hundreds of thousands of individuals worldwide every year.
NVLX has taken some HUGE steps forward recently, placing the Company in an excellent position for growth. They have released quite a few significant press releases including today`s breaking news all of which indicate the Company`s Huge Growth potential and there continued ability to hit their Millstones.
NVLX looks to be setting up for a Major Breakout! The strong momentum pushing NVLX means that the bullish upside could lead to a major breakout any minute! I believe we have found what could be the hottest play we have had in recent months… And you all know we are coming off of some huge winners.
If you haven`t taken a look at NVLX yet, this may be the last chance in this range! Start your research immediately at:
www.nuvilex.com Sincerely, Ari Goldstein Editor In Chief, EquityTradingAlert PS. My Incredible Winning Streak Set to Continue! We are Coming off of winners that gained 100% while others witnessed 300%+ within the first hour of trading.
PPS. To make sure you take full advantage of our Newsletter make sure you add our email address: email@example.com to your email program`s safe sender list to ensure that you receive our Newsletter! This will ensure our emails don`t end up in the spam box.
DON`T MISS ANOTHER HOT OPPORTUNITY TO MAKE HUGE PROFITS! GENERAL NOTICE AND DISCLAIMER – PLEASE READ CAREFULLY Please be advised that we have been compensated seven thousand five hundred dollars cash by ACN LLC, a non-affiliated third party to profile NVLX for a two day investor awareness program. WE OWN NO SHARES.
Equity Trading Alert 4417 13th St. Saint Cloud, FL 34769 To
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Call to Action —————————————————————– Hot Stock to Watch —————————————————————– Company: Terra Tech Corp (OTCQB: TRTC) End of Day:
Price: 0.274 Change (%): – 0.015 (5.19) Volume: 1,181,178 http://app.getresponse.com/click.htmlx=a62b&lc=Jx1po&mc=Bu&s=V2HFR&u=BEqW&y=b& Terra Tech Corp. Secures Equity Line With Magna Equities II, LLC Irvine, Jan. 6, 2015 (GLOBE NEWSWIRE) – Terra Tech Corp. (TRTC) today announced that it obtained a committed equity line under which it may from time to time sell up to 57,000,000 shares of its common stock to Magna Equities II, LLC over a 24-month period following the effectiveness of a re-sale registration statement that Terra Tech filed with the Securities and Exchange Commission on December 24, 2014. Terra Tech will determine, in its sole discretion, the timing, price and amount of the draws. The purchase price of each share will be equal to 95% of the market price during the five consecutive trading days immediately preceding the date of the applicable draw down, with the market price equal to the average of the three lowest VWAPs of the common stock in the five trading day period immediately preceding the date of the applicable draw down notice. Terra Tech intends to use the net proceeds from any sale of common stock under the equity line to execute its growth strategy, to aid in the commercial development of its subsidiaries, and for general corporate purposes.
In connection with its execution of the equity line documents, Terra Tech issued 416,667 shares of its restricted common stock to Magna as a commitment fee. The offer and sale of shares of common stock by Terra Tech under the equity line is and will be pursuant to an exemption from the registration requirements of Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D promulgated thereunder.
Continue Reading – http://app.getresponse.com/click.htmlx=a62b&lc=Jx11w&mc=Bu&s=V2HFR&u=BEqW&y=v& —————————————————————– Company: Pazoo Inc. (OTCQB: PZOO) End of Day:
Price: 0.0147 Change (%): – 0.0012 (7.55) Volume: 1,851,568 http://app.getresponse.com/click.htmlx=a62b&lc=Jx1bT&mc=Bu&s=V2HFR&u=BEqW&y=B& Pazoo.com Inspiration Expert Jenna Lowthert Launches New Blog, Book, and Radio Interview WHIPPANY, N.J., Jan. 7, 2015 (GLOBE NEWSWIRE) – Pazoo, Inc.
(OTCQB Symbol:PZOO) (German WKN#: A1J3DK) is pleased to announce that Pazoo’s Inspiration Expert Jenna Lowthert has launched a new blog at http://app.getresponse.com/click.htmlx=a62b&lc=Jx1N0&mc=Bu&s=V2HFR&u=BEqW&y=5& Jenna also has a new book (Life Goes On) and will be interviewed on the radio program called Issues Today, hosted by Bob Gourley, syndicated on 183 stations throughout the USA. To listen live go to www.issuestodayradio.com. Jenna will be interviewed on January 14, 2015.
In just the short few weeks that Jenna’s blog has been up, Pazoo.com has experienced several thousand additional visitors per day to the website. It is expected that this blog will continue to grow in popularity helping to bring continued growth in traffic to Pazoo.com. Expanding upon this will be additional blogs with the next two being a military health and wellness blog as well as a marijuana blog. These blogs, along with the addition of several more topic intensive blogs, are expected to be not only inspirational but big traffic drivers to Pazoo.com.
Continue Reading – http://app.getresponse.com/click.htmlx=a62b&lc=Jx17a&mc=Bu&s=V2HFR&u=BEqW&y=9& —————————————————————– Other Small Cap News —————————————————————– Company: Nuvilex, Inc. (OTCQB: NVLX) http://app.getresponse.com/click.htmlx=a62b&lc=Jx1qP&mc=Bu&s=V2HFR&u=BEqW&y=d& Nuvilex Announces Name Change to PharmaCyte Biotech Company`s Shares Will Trade Under New Ticker Symbol PHCB SILVER SPRING, Md., Jan. 7, 2015 (GLOBE NEWSWIRE) — Nuvilex, Inc. (OTCQB:NVLX) today announced that the Company has changed its name to PharmaCyte Biotech, Inc. Shares in PharmaCyte Biotech will trade under the new ticker symbol “PHCB” on the OTCQB electronic platform. The new symbol is expected to become effective at the open of the market on January 8, 2014. The name change is part of the Company`s transformation process to operate solely as a pure biotechnology firm leveraging its Cell-in-a-Box® technology, a proprietary cell encapsulation platform being utilized to develop “targeted” treatments for solid cancerous tumors and insulin dependent diabetes.
“Over the past year, we`ve implemented an aggressive strategy to facilitate the advancement of the treatments we are developing for cancer and diabetes, with our Cell-in-a-Box® technology at the core of these treatments. Our new name reflects the tremendous progress we`ve accomplished in terms of clinical development and signifies the structural completion of our transition to becoming a fully dedicated biotechnology company,” said Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
Continue Reading – http://app.getresponse.com/click.htmlx=a62b&lc=Jx1nt&mc=Bu&s=V2HFR&u=BEqW&y=e& —————————————————————– Company: Sino Agro Food, Inc. (OTCQB: SIAF) http://app.getresponse.com/click.htmlx=a62b&lc=Jx1D1&mc=Bu&s=V2HFR&u=BEqW&y=G& Agricultural Development Bank of China Doubles Bank Loan to Sino Agro Food Subsidiary, Sanjiang A Power Agriculture Co. (“SJAP“) GUANGZHOU, China, Jan. 7, 2015 /PRNewswire/ — Sino Agro Food, Inc. (OTCQB: SIAF) is an integrated, diversified agriculture technology and organic food company (the “Company”) with principal operations as primary producer, processor, and marketer in the People`s Republic of China (“PRC”).
Agricultural Development Bank of China (“ADBC“) has doubled its loan facilities to SJAP to 80M RMB (from 40M RMB). In November 2014, Sino Agro announced it would evaluate and explore proposed listing and M&A opportunities for SJAP, its integrated cattle farm subsidiary.
Continue Reading – http://app.getresponse.com/click.htmlx=a62b&lc=Jx14X&mc=Bu&s=V2HFR&u=BEqW&y=x& —————————————————————– Market News —————————————————————– By Suzanne O`Halloran: Yahoo Finance January`s tidal wave of events will keep trading choppy We are just three trading days into 2015 and already investors have been whipsawed by 200 to 300 point intraday swings in the Dow Jones Industrials. Investors looking for a little relief are out of luck, cautions Peter Kenny, chief market strategist at Clearpool Group, who expects January’s jitters to persist through the end of the month. “We have other things going on that are going to really drive this volatility conversation,” he notes.
On January 22 the European Central Bank will meet. Late last year ECB President Mario Draghi indicated the central bank would take the necessary steps to prop up the eurozone’s economy. Since then Greece has re-emerged as a fissure to the region, creating a new wrinkle of uncertainty Kenny says. “What does the ECB do to stimulate growth in the European Union and how does it handle Greece” Continue Reading – http://app.getresponse.com/click.htmlx=a62b&lc=Jx16E&mc=Bu&s=V2HFR&u=BEqW&y=l& —————————————————————– By Abigail Stevenson: CNBC Cramer: Charts predict the best year to own stocks In a couple of months, the raging bull of the stock market will turn six years old. The average bull market only lasts five years, and Jim Cramer is wondering if investors need to start worrying about the health of the bull.
To find the answer, Cramer once again turned to the charts to see what they predict. He has taken a step back with Ed Ponsi to take a good look at the big picture for the averages. Ponsi is a technician and managing director of Barchetta Capital Management, as well as Cramer`s colleague at RealMoney.com.
Continue Reading – http://app.getresponse.com/click.htmlx=a62b&lc=JxbEU&mc=Bu&s=V2HFR&u=BEqW&y=D& —————————————————————– IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY —————————————————————– SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies.
You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research.
You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. opt out of our distribution list at any time by clicking on the “